In 1997 Marmion joined Royal College of Surgeons in Ireland as a lecturer in the Department of Chemistry.[2] She was promoted to Associate Professor in 2013 and Professor in 2018. Her research considers the design of metal-based chemotherapeutic drugs. In particular, this has included the design of targeted PtIV prodrugs.[4][5]Immunodeficient cancer patients are at risk of developing infections, which occasionally require antimicrobialprophylaxis. To better serve these patients Marmion developed a family of metallo-antibiotics, based on a Cu-N,N-framework, which can bind to DNA, has DNA oxidant properties and has antiproliferative and antimicrobial properties.[6] Her research has been supported by the Science Foundation Ireland (SFI) to create a prodrug strategy for multi-modal chemotherapeutics.[7]
Marmion, Celine (2019). Metal-based Anticancer Agents. Royal Society of Chemistry. ISBN9781788014069.
Marmion, Celine J. (2004). "Hydroxamic Acids− An Intriguing Family of Enzyme Inhibitors and Biomedical Ligands". European Journal of Inorganic Chemistry. 2004 (15): 3003–3016. doi:10.1002/ejic.200400221.
Marmion, Celine J. (2000). "Hydroxamic acids are nitric oxide donors. Facile formation of ruthenium(II)-nitrosyls and NO-mediated activation of guanylate cyclase by hydroxamic acids". Chemical Communications (13): 1153–1154. doi:10.1039/B001631O.
References
^Dublin, T. U. "TU Dublin News". www.dit.ie. Retrieved 13 January 2020.